Table 1.
αIIbβ3 integrin receptor antagonist drugs.
| Drug | Product Availability | FDA-Approved Indications 4 | Clinical Trial |
|---|---|---|---|
| Abciximab 1 (ReoPro) | 5 mL vial (2 mg/mL) | PCI only | EPIC |
| Eptifibatide 2 (Integrilin) | a. 100 mL (750 µg/mL) | Unstable Angina/NSTEMI/PCI | PURSUIT |
| b. 10 mL/vial (2000 µg/mL) | ESPRIT | ||
| c. 100 mL/vial (2000 µg/mL) | IMPACT-II | ||
| Tirofiban 3 (Aggrastat) | a. 250 mL (50 µg/mL) | Unstable Angina / NSTEMI only | PRISM |
| b. 500 mL (50 µg/mL) | PRISM-PLUS | ||
| c. 25 mL/vial (250 µg/mL) | RESTORE | ||
| d. 50 mL /vial (250 µg/mL) | TARGET |
1 Manufactured by Centocor/Eli Lily, 2 Manufactured by COR/Key, Glaxo, Bayer, etc. 3 Manufactured by Merck, Abbott, etc.-alternative names: L-462; MK 383; 4 PCI = Percutaneous Coronary Intervention (stent, balloon angioplasty, therectomy, rotablation); NSTEMI—non St segment elevation (on the electrocardiography) myocardial infarction.